A Biospecimen and Clinical Data Study on Patients for Drug & Biomarker Discovery

NCT01592552 | Completed

• 1 other identifier: SAN-ND-01
• Study Type: observational
• Target: 20
• Locations: 1 country
• Sites: 1

Brief Summary

The purpose of this research project is to collect and store blood samples and clinical data. Researchers can then use the stored samples in future studies. Through such studies, they hope to find new ways to detect, treat, and maybe even prevent or cure health problems.

Conditions

Alzheimer's Disease; Multiple Sclerosis; Parkinson's Disease; Huntington's Disease; Amyotrophic Lateral Sclerosis (ALS)

Keywords

Alzheimer's Disease; Multiple Sclerosis; Parkinson's Disease; Huntington's Disease; Amyotrophic Lateral Sclerosis (ALS)

Outcome Measures

Primary Outcomes (1)

• Biospecimens & Clinical Data collection from patients with neurological diseases.

  The purpose of this research project is to collect and store blood samples and clinical data. Researchers can then use the stored samples in future studies. Through such studies, they hope to find new ways to detect, treat, and maybe even prevent or cure health problems.

  2 years

Study Arms (2)

Neurological Condition

Collect blood and other biospecimens like saliva, urine and CSF for research purposes.

Control

Collect blood and other biospecimens like saliva, urine and CSF for research purposes.

Eligibility Criteria

• Age: 18 Years - 100 Years
• Sex: all
• Healthy Volunteers: Yes
• Age Groups: Adult (18-64), Older Adult (65+)
• Sampling Method: Non-Probability Sample

Study Population

A diagnosis of Multiple Sclerosis, Alzheimer's, Huntington's, or Parkinson's Disease.

You may qualify if:

• Males and females \>18 to 100 years old
• A diagnosis of neurological condition
• Proof of diagnosis can be provided
• Control group: Healthy donors, males and females, 18 to 100 years of age

You may not qualify if:

• Receipt of blood products within 30 days of study enrollment
• Receipt of an investigational (unapproved) drug within 30 days of study enrollment

Sponsors & Collaborators

• Sanguine Biosciences: lead

Study Sites (1)

Sanguine Biosciences

Sherman Oaks, California, 91403, United States

Location

MeSH Terms

Conditions

Alzheimer Disease; Multiple Sclerosis; Parkinson Disease; Huntington Disease; Amyotrophic Lateral Sclerosis

Condition Hierarchy (Ancestors)

Dementia; Brain Diseases; Central Nervous System Diseases; Nervous System Diseases; Tauopathies; Neurodegenerative Diseases; Neurocognitive Disorders; Mental Disorders; Demyelinating Autoimmune Diseases, CNS; Autoimmune Diseases of the Nervous System; Demyelinating Diseases; Autoimmune Diseases; Immune System Diseases; Parkinsonian Disorders; Basal Ganglia Diseases; Movement Disorders; Synucleinopathies; Chorea; Dyskinesias; Heredodegenerative Disorders, Nervous System; Genetic Diseases, Inborn; Congenital, Hereditary, and Neonatal Diseases and Abnormalities; Cognition Disorders; Spinal Cord Diseases; Motor Neuron Disease; TDP-43 Proteinopathies; Neuromuscular Diseases; Proteostasis Deficiencies; Metabolic Diseases; Nutritional and Metabolic Diseases

Study Officials

• Phil Silkoff, MD

  Sanguine Biosciences

  PRINCIPAL INVESTIGATOR

Study Design

• Study Type: observational
• Observational Model: COHORT
• Time Perspective: CROSS SECTIONAL
• Sponsor Type: INDUSTRY
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: November 16, 2011
• First Posted: May 7, 2012
• Study Start: November 1, 2011
• Primary Completion: March 1, 2015
• Study Completion: March 1, 2015
• Last Updated: November 22, 2023

Record last verified: 2023-11

Locations

US (1)